Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety of single doses of orally
administered EDP-788.
Secondary objectives of the study are:
- To describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after single
doses of orally administered drug
- To estimate the bioavailability of EDP-788 capsules relative to an oral liquid
suspension
- To estimate the effect of co-administration of food on the absorption of EDP-788